Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.03.02

ISO 14001:2015 & ISO 45001:2018

Sai Life Sciences receives ISO 14001:2015 and ISO 45001:2018 certification

Sai Life Sciences received the ISO 14001:2015 (Environment management system) and ISO 45001:2018 (Occupational health and safety management system) certification for its R&D centre (Unit II), Manufacturing facility (Unit IV) and Corporate office. Certified by Bureau Veritas, it reflects the organization’s commitment towards continually improving its health, safety & environment performance.

Responding to the development, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences said, “We have always considered Health, Safety and Environment (HSE) to be a fundamental component of our long-term business strategy. Receiving the internationally recognized ISO certification is a validation of our commitment to continual improvement.”

Sai Life Sciences follows a proactive approach to minimize environment footprint and occupational hazards through structured environment impact assessments and risk assessments. It has a dedicated process safety lab to study thermal stability and powder safety aspects and has achieved Zero Liquid Discharge in its manufacturing facility.

Additionally, as part Sai Nxt, an org-wide transformation initiative currently underway, the company has made several improvements to its HSE practices:

  1. Established in-house capability for monitoring chemical exposure, heat stress, personal noise dosimetry to personnel
  2. Invested in production trains with advanced containment systems capable of minimising chemical exposure below 1 µg/m3
  3. Achieved zero waste to landfill
  4. Adopted Green Chemistry principles in process development

Sai Life Sciences has been awarded Silver Medal in the EcoVadis CSR assessment, 5-Star rating (Excellence in EHS Practices) at the CII-Southern region EHS excellence awards and has been successfully audited multiple times as per the Pharmaceutical Supply Chain Initiative (PSCI) framework.

Share article

More News

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more

2025.08.13

Peptide Science & Beyond: Masterclass & Fireside Chat with IISc Professor, Dr. Jayanta Chatterjee

Sai Life Sciences recently hosted Dr. Jayanta Chatterjee, Associate Professor at the Indian Institute of Science (IISc), Bangalore, for two enriching sessions at its campus. The first was the Masterclass Lecture Series, where Dr. Chatterjee addressed a group of scientists at Sai Life Sciences on “Our Adventures in the de novo Design of Helical Macrocyclic […]
Read more

2025.08.13

From vendor to vanguard: Reimagining India’s role in global life sciences

In a recent article published in ET Edge titled, ‘From Vendor to Vanguard: Reimagining India’s Role in Global Life Sciences,’ Krishna Kanumuri, MD & CEO, Sai Life Sciences, highlighted India’s rapidly unfolding transformation from a vendor to an innovation leader in the global life sciences ecosystem.You can read the full article here: From vendor to vanguard: […]
Read more

2025.08.08

Sai Life Sciences Limited Reports Revenue growth of 77% YoY

Q1FY26 Revenue at ₹496 Cr; EBITDA at ₹125 Cr; Net Profit at ₹60 Cr. Hyderabad, August 08, 2025: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research, Development and Manufacturing Organization (CRDMO) announced its financial results for the first quarter of Fiscal year 2026. Financial Performance: Particulars (₹ crores) Q1FY26 […]
Read more